VidatoX is a drug produced from five protein peptides extracted from the venom of the blue scorpion (Rophalorus junceus), which is endemic to Cuba and which has analgesic, anti-inflammatory and anti-carcinogenic effect in more than 15 different cancer cell lines. The result of 15 years of research, by October 2010 Vidatox had been tested on more than 10,000 cancer patients, some 3,500 of them foreigners, with positive results both in improving quality of life and stopping tumour growth.